FAQs & How to use this site
Home | About Us | Contact Us
The Front Line

 

The Front Line: Charles D. Blanke, MD, SWOG Chair
ABOUT

PREVIOUS POSTS April 2017

Bumper Crop of Young Investigators to Train in Seattle

September 2, 2016 - Last week, we reviewed applications and selected the 2016 participants for our Young Investigator Training Course (YITC) to be held in Seattle from Sept. 26-28. Its a notable group. Its the first all-female cohort to be selected in 13 years. Its also one of the most accomplished pool of early career investigators weve had in years, all bringing great training, a proven commitment to SWOG, and exciting clinical trial ideas to the table.

As you know from these Front Line posts, my leadership team this year made improvements to the process for nominating and selecting YITC participants. Its important that process is robust and smooth. The YITC is SWOGs premier education opportunity for early career investigators, and remains a major way that new trials and new leaders get into our network.

Executive officers, committee chairs, and senior investigators worked hard to advocate for good candidates and strong trial concepts, and to be sure people and projects and SWOG are a good fit. Their efforts paid off. Here is the YITC class for 2016 with their trial topics:

Uma M. Borate, MD, MS, Oregon Health & Science University

Phase II Study of Brentuximab Vedotion in Systemic Mastocytosis and Chronic Myelomonocytic Leukemia

Erin F. Cobain, MD, University of Michigan

PeRsistently Elevated CTCs in chemotherapy-refractory metastatic breast cancer treated with combination immune CHEcKpoint inhibition (PRE-CHEK)

Kristen M. O'Dwyer, MD, University of Rochester Medical Center

Treatment Response Adapted Therapy for Adolescents and Young Adults (AYAs) with Acute Myeloid Leukemia

Emma C. Scott, MD, Oregon Health & Science University

A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis

Virginia Sun, RN, PhD, City of Hope

A Personalized Dietary Intervention to Manage Bowel Dysfunction in Rectal Cancer Survivors

Cecilia C.S. Yeung, MD, Fred Hutchinson Cancer Research Center

AKR1C3 and POR expression for activation of PR- 104 in Relapsed/ Refractory T-ALL

Its worth noting that the YITC was launched in 1998. Not quite 60 years, but since then, 81 young cancer researchers have graduated from the YITC. This has resulted in the activation of more than 40 trials. And many trainees have become leaders within the group. This is a great return on a modest investment, and its why we support this program each year.

 
     
SWOG Logo Disclaimer | Copyright ©2000-2017 SWOG. All rights reserved.
Design by nuMedia Group Inc. | Hosting by WorldPost Technologies, Inc.
SWOG is FISMA CertifiedSWOG is FISMA Certified